SCHEDULE: FMR LLC Discloses 3% Stake in Cartesian Therapeutics

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 3.0% of Cartesian Therapeutics' common stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, indicating their beneficial ownership of Cartesian Therapeutics Inc. common stock.
• As of March 31, 2026, the total number of shares beneficially owned by FMR LLC and Abigail P. Johnson is 799,743.
• This represents 3.0% of the total outstanding shares of Cartesian Therapeutics Inc. common stock.
• FMR LLC is classified as an Investment Adviser (IA) and a Broker or dealer registered under section 15 of the Act.
• Abigail P. Johnson is identified as an Insider (IN) and is a Director, Chairman, and CEO of FMR LLC.
• The filing confirms that no single reporting person holds more than 5% of the class of securities.
• A Rule 13d-1(k)(1) agreement for joint filing is in place, effective May 5, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it indicates institutional interest but does not provide new operational or financial performance data for Cartesian Therapeutics.

Positives

• FMR LLC, a significant investment management firm, has taken a position in Cartesian Therapeutics, which could signal confidence in the company's prospects.
• The disclosure indicates a substantial, though not controlling, stake, suggesting a belief in the company's value.
• The filing is current and adheres to regulatory requirements, providing transparency to the market.

Negatives

• The ownership stake of 3.0% is relatively small and does not represent a controlling interest, limiting FMR LLC's direct influence on corporate decisions.
• The filing does not provide details on the acquisition cost or strategy behind this investment.

Risks

• The filing does not explicitly mention any risks associated with Cartesian Therapeutics.
• Potential future regulatory changes or market shifts could impact the value of the investment.
• The performance of Cartesian Therapeutics' drug development pipeline represents an inherent risk to the investment.

Future Outlook

The filing itself is a historical disclosure of ownership as of a specific date and does not contain forward-looking statements or guidance from Cartesian Therapeutics. FMR LLC's future actions regarding this stake are not disclosed.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
• The filing notes that members of the Johnson family may be deemed controlling group with respect to FMR LLC through ownership of voting common shares and a shareholders' voting agreement.

Industry Context

StockSavvy.ai notes that institutional investment, as indicated by FMR LLC's filing, is a common indicator of potential growth or stability in the biotechnology sector. Cartesian Therapeutics operates in the clinical-stage biotechnology space, where significant institutional backing can be crucial for advancing drug development pipelines.

Stakeholder Impact

• Shareholders: Increased visibility due to investment by a large financial institution, potentially attracting further investor interest.
• Management: May face increased scrutiny or engagement from FMR LLC regarding corporate strategy and performance.
• Creditors: No direct impact indicated by this filing.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to hold their shares in Cartesian Therapeutics Inc.
• Future filings will be made if their beneficial ownership changes significantly (e.g., crosses 5% threshold).

Key Dates

Keywords

Cartesian Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Biotechnology, Healthcare